Compare Medtronic PLC (MDT) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Monster Beverage Corp — how do they compare? Medtronic PLC trades at $90.8 (market cap $116.07B), while Monster Beverage Corp trades at $45.62 (market cap $89.20B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays a 3.18% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MDT | MNST | |
|---|---|---|
Market Cap | $116.07B | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $49.97 |
52-Week Low | $73.75 | $30.86 |
Enterprise Value | $134.82B | $87.49B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Monster Beverage (MNST) trades at $45.53, down 0.35% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, maintaining robust profit margins above 23%. Recent Q2 2026 results exceeded expectations with $0.60 EPS versus $0.59 expected, driven by international growth. The stock completed a 2-for-1 split on August 11, 2026.
MNST presents a mixed outlook with strong earnings momentum and international expansion offset by premium valuation concerns. The stock trades at 42.16x P/E, above sector averages, while analyst consensus targets $51.14 suggest 12% upside. Key risks include competitive pressures in energy drinks and valuation sensitivity to growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
